Advances in tumor immunotherapy
10.3760/cma.j.cn121382-20230822-00501
- VernacularTitle:肿瘤免疫治疗研究进展
- Author:
Jiahui CAO
1
;
Dunwan ZHU
;
Linhua ZHANG
Author Information
1. 中国医学科学院 北京协和医学院生物医学工程研究所，天津 300192
- Keywords:
Tumor immunotherapy;
Monoclonal antibody therapy;
Immune checkpoint inhibitor therapy;
Immunocell therapy;
Tumor vaccines
- From:
International Journal of Biomedical Engineering
2023;46(5):377-383
- CountryChina
- Language:Chinese
-
Abstract:
Tumor immunotherapy has become the main treatment method for cancer after surgery, radiotherapy and chemotherapy. With the in-depth study of tumor immunology, cell biology and molecular technology, the tumor microenvironment was found to be immunosuppressive, and tumor development and metastasis are closely related to it. Tumor immunotherapy uses the body’s own immune system to kill tumor cells. At present, there are mainly mainstream tumor immunotherapy methods, namely monoclonal antibody therapy, immune checkpoint inhibitor therapy, immunocell therapy, and tumor vaccines. In this paper, the advantages and limitations of these four immunotherapies were mainly discussed, and the current status of their marketing and clinical research was also reviewed.
